이스라엘 - 영어 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - atorvastatin as calcium - film coated tablets - atorvastatin as calcium 20 mg - atorvastatin - atorvastatin - lipitor is indicated as an adjunct to diet for reduction of elevated total cholesterol ldl- cholesterol apolipoprotein b and triglycerides and to increase hdl cholesterol in patients with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to types iia and iib of the fredrickson classification) when response to diet and other nonpharmacological measures is inadequate. lipitor is also indicated to reduce total-c and ldl -c in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatment (e.g. ldl apheresis) or if such treatments are unavailable. pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient. prevention of cardiovascular and/or cerebrovascular event sush as mi or stroke as an adjunct to correction of other risk factors such as hypertension in patients with three or more additional risk factors or diabetes with one additional risk factor. in patients with clinically evident coronary heart disease lipitor is indicated to : reduce the risk of non-fatal myocardial infarction. reduce the risk of fatal and non fatal stroke. reduce the risk for revascularization procedures. reduce the risk of hospitalization for chf. reduce the risk of angina.

이스라엘 - 영어 - Ministry of Health

teva medical marketing ltd. - glucose as monohydrate; glycine; l- alanine; l- isoleucine; l- leucine; l- lysine as hydrochloride; l- methionine; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; refined soya-bean oil - emulsion for infusion - refined soya-bean oil 200 g / 1000 ml; glucose as monohydrate 400 g / 1000 ml; l- valine 5.80 g / 1000 ml; l- tyrosine 0.40 g / 1000 ml; l- tryptophan 1.80 g / 1000 ml; l- threonine 4.20 g / 1000 ml; l- serine 5.00 g / 1000 ml; l- proline 6.80 g / 1000 ml; l- phenylalanine 5.60 g / 1000 ml; l- methionine 4.00 g / 1000 ml; l- lysine as hydrochloride 5.80 g / 1000 ml; l- leucine 7.30 g / 1000 ml; l- isoleucine 6.00 g / 1000 ml; l-histidine 4.80 g / 1000 ml; glycine 10.30 g / 1000 ml; l-arginine 11.50 g / 1000 ml; l- alanine 20.70 g / 1000 ml - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

유럽 연합 - 영어 - EMA (European Medicines Agency)

astellas pharma europe b.v. - micafungin - candidiasis - antimycotics for systemic use - mycamine is indicated for:adults, adolescents ≥ 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.the decision to use mycamine should take into account a potential risk for the development of liver tumours. mycamine should therefore only be used if other antifungals are not appropriate.

이스라엘 - 영어 - Ministry of Health

teva medical marketing ltd. - calcium chloride dihydrate; glucose as monohydrate; glycine; l- alanine; l- isoleucine; l- leucine; l- lysine as hydrochloride; l- methionine; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; magnesium chloride hexahydrate; potassium chloride; refined soya-bean oil; sodium acetate trihydrate; sodium glycerophosphate pentahydrate - emulsion for infusion - glycine 5.67 g / 1000 ml; l- alanine 11.39 g / 1000 ml; l-histidine 2.64 g / 1000 ml; l-arginine 6.33 g / 1000 ml; l- methionine 2.20 g / 1000 ml; l- lysine as hydrochloride 3.19 g / 1000 ml; l- isoleucine 3.30 g / 1000 ml; l- threonine 2.31 g / 1000 ml; l- tryptophan 0.99 g / 1000 ml; l- proline 3.74 g / 1000 ml; l- phenylalanine 3.08 g / 1000 ml; l- valine 3.19 g / 1000 ml; l- tyrosine 0.22 g / 1000 ml; l- leucine 4.02 g / 1000 ml; l- serine 2.75 g / 1000 ml; sodium glycerophosphate pentahydrate 5.36 g / 1000 ml; sodium acetate trihydrate 2.45 g / 1000 ml; refined soya-bean oil 100 g / 1000 ml; calcium chloride dihydrate 0.74 g / 1000 ml; glucose as monohydrate 200 g / 1000 ml; potassium chloride 2.98 g / 1000 ml; magnesium chloride hexahydrate 1.12 g / 1000 ml - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

이스라엘 - 영어 - Ministry of Health

teva medical marketing ltd. - calcium chloride dihydrate; glucose as monohydrate; glycine; l- alanine; l- isoleucine; l- leucine; l- lysine as hydrochloride; l- methionine; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; magnesium chloride hexahydrate; potassium chloride; refined soya-bean oil; sodium acetate trihydrate; sodium glycerophosphate pentahydrate - emulsion for infusion - refined soya-bean oil 200.00 g / 1000 ml; calcium chloride dihydrate 0.74 g / 1000 ml; glucose as monohydrate 250.00 g / 1000 ml; magnesium chloride hexahydrate 1.12 g / 1000 ml; potassium chloride 4.47 g / 1000 ml; sodium glycerophosphate pentahydrate 5.36 g / 1000 ml; sodium acetate trihydrate 6.12 g / 1000 ml; l- valine 4.06 g / 1000 ml; l- tyrosine 0.28 g / 1000 ml; l- tryptophan 1.26 g / 1000 ml; l- threonine 2.94 g / 1000 ml; l- serine 3.50 g / 1000 ml; l- proline 4.76 g / 1000 ml; l- phenylalanine 3.92 g / 1000 ml; l- methionine 2.80 g / 1000 ml; l- lysine as hydrochloride 4.06 g / 1000 ml; l- leucine 5.11 g / 1000 ml; l- isoleucine 4.20 g / 1000 ml; l-histidine 3.36 g / 1000 ml; glycine 7.21 g / 1000 ml; l-arginine 8.05 g / 1000 ml; l- alanine 14.49 g / 1000 ml - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

이스라엘 - 영어 - Ministry of Health

teva medical marketing ltd. - calcium chloride dihydrate; glucose as monohydrate; glycine; l- alanine; l- isoleucine; l- leucine; l- lysine as hydrochloride; l- methionine; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; magnesium chloride hexahydrate; potassium chloride; refined olive oil; sodium acetate trihydrate; sodium glycerophosphate pentahydrate - emulsion for infusion - l- alanine 17.60 g / 1000 ml; refined olive oil 200 g / 1000 ml; calcium chloride dihydrate 0.74 g / 1000 ml; glucose as monohydrate 300 g / 1000 ml; magnesium chloride hexahydrate 1.12 g / 1000 ml; potassium chloride 4.47 g / 1000 ml; sodium glycerophosphate pentahydrate 5.36 g / 1000 ml; sodium acetate trihydrate 6.12 g / 1000 ml; l- valine 4.93 g / 1000 ml; l- tyrosine 0.34 g / 1000 ml; l- tryptophan 1.53 g / 1000 ml; l- threonine 3.57 g / 1000 ml; l- serine 4.25 g / 1000 ml; l- proline 5.78 g / 1000 ml; l- phenylalanine 4.76 g / 1000 ml; l- methionine 3.40 g / 1000 ml; l- lysine as hydrochloride 4.93 g / 1000 ml; l- leucine 6.21 g / 1000 ml; l- isoleucine 5.10 g / 1000 ml; l-histidine 4.08 g / 1000 ml; glycine 8.76 g / 1000 ml; l-arginine 9.78 g / 1000 ml - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

이스라엘 - 영어 - Ministry of Health

teva medical marketing ltd. - calcium chloride dihydrate; glucose as monohydrate; glycine; l- alanine; l- isoleucine; l- leucine; l- lysine as hydrochloride; l- methionine; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; magnesium chloride; potassium chloride; refined soya-bean oil; sodium acetate dihydrate; sodium glycerophosphate - emulsion for infusion - refined soya-bean oil 200 g / 1000 ml; calcium chloride dihydrate 0.74 g / 1000 ml; glucose as monohydrate 4000.00 g / 1000 ml; magnesium chloride 1.12 g / 1000 ml; potassium chloride 4.47 g / 1000 ml; sodium glycerophosphate 5.36 g / 1000 ml; sodium acetate dihydrate 6.12 g / 1000 ml; l- valine 5.80 g / 1000 ml; l- tyrosine 0.40 g / 1000 ml; l- tryptophan 1.80 g / 1000 ml; l- threonine 4.20 g / 1000 ml; l- serine 5.00 g / 1000 ml; l- proline 6.80 g / 1000 ml; l- phenylalanine 5.60 g / 1000 ml; l- methionine 4.00 g / 1000 ml; l- lysine as hydrochloride 5.80 g / 1000 ml; l- leucine 7.30 g / 1000 ml; l- isoleucine 6.00 g / 1000 ml; l-histidine 4.80 g / 1000 ml; glycine 10.30 g / 1000 ml; l-arginine 11.50 g / 1000 ml; l- alanine 20.70 g / 1000 ml - parenteral nutrition for adults and children above 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clopidogrel besilate, quantity: 112.1 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: mannitol; polyethylene glycol monomethyl ether; iron oxide red; stearic acid; hyprolose; purified talc; citric acid monohydrate; hypromellose; lactose monohydrate; microcrystalline cellulose; triacetin; crospovidone; titanium dioxide - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome: plidogrel is indicated in combination with aspirin for patients with: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). plidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent); st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, plidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

미국 - 영어 - NLM (National Library of Medicine)

rxhomeo private limited d.b.a. - kalmia latifolia leaf (unii: 79n6542n18) (kalmia latifolia leaf - unii:79n6542n18) - kalmia latifolia leaf 3 [hp_x]

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - rituximab, quantity: 10 mg/ml - injection, concentrated - excipient ingredients: polysorbate 80; sodium chloride; water for injections; sodium hydroxide; hydrochloric acid; citric acid; sodium citrate dihydrate - non-hodgkin's lymphoma: mabthera is indicated for treatment of patients with: cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin's lymphoma. cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma, cd20 positive, diffuse large b-cell non-hodgkin's lymphoma, in combination with chemotherapy. chronic lymphocytic leukaemia: mabthera is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy. rheumatoid arthritis: mabthera (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with severe, active rheumatoid arthritis who have had an inadequate response or intolerance to at least one tumour necrosis factor (tnf) inhibitor therapy. mabthera has been shown to reduce the rate of progression of joint damage as measured by x-ray when given in combination with methotrexate. granulomatosis with polyangiitis (wegener's ) (gpa) and microscopic poly